Adcetris brentuximab vedotin injectable medication precertification request page 1 of 2. Brentuximab vedotin with chemotherapy for stage iii or iv. Study of brentuximab vedotin combined with rchop or rchp. It is also known by its full name brentuximab vedotin and its brand name, adcetris. Adcetris brentuximab vedotin for injection is supplied as a sterile, white to offwhite, preservativefree lyophilized cake or powder in singledose vials. Nov 26, 2018 adcetris brentuximab vedotin for injection is supplied as a sterile, white to offwhite, preservativefree lyophilized cake or powder in singledose vials. Brentuximab vedotin is an antibody and chemotherapy. Brentuximab vedotin an overview sciencedirect topics. Data sources include ibm watson micromedex updated 4 may 2020, cerner multum updated 4 may 2020. Safety and efficacy of brentuximab vedotin for hodgkin lymphoma. Frontline brentuximab plus avd vs standard abvd in. If remission is achieved, some patients may receive a bone marrow transplant with the goal of cure. Complete remission of relapsed hodgkins lymphoma following.
Bv binds to extracellular domain of cd30 and is internalized and subsequently transferred to the lysosome causing enzymatic cleavage of the linker peptide and release. It attaches to the cd30 a protein on the surface of cancer cells. Superior outcomes with brentuximab vedotin in cutaneous t cell lymphoma. Brentuximab vedotin is an antibodydrug conjugate that specifically targets the tnf receptor superfamily member 8 cd30 antigen on the surface of cancer cells to induce cell death.
Brentuximab adcetris medical clinical policy bulletins. Patients must be at least 3 months from the last dose of bv. See full prescribing information for complete boxed warning. The data were presented at the 56th american society of hematology ash annual meeting and. Brentuximab vedotin is an antibody drug conjugate adc composed of a chimeric monoclonal antibody cac10 linked to an antitubulin agent, monomethylauristatin e mmae. Based on the efficacy and tolerability of brentuximab vedotin in patients who had undergone autosct. Brentuximab vedotin bv, an anticd30 drug, presents as an effective. Robert eisenberg, in stiehms immune deficiencies, 2014. Although the majority of individuals with hodgkin lymphoma hl experience durable remissions after modern first. Feb 15, 2020 patients with cancer who take brentuximab vedotin may be at a greater risk of getting a severe health problem called tumor lysis syndrome tls. Adcetris is approved in more than 45 countries, including brazil, japan, the united states and countries in the european union.
This extract does not include sections from the cer regarding product documentation or post market activities. Get emergency medical help if you have signs of an allergic reaction hives, difficult breathing, swelling in your face or throat or a severe skin reaction fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling. The united states food and drug administration fda recently approved brentuximab vedotin in combination with chemotherapy as a firstline treatment for people with advancedstage classical hodgkin lymphoma also known as adcetris, brentuximab vedotin is an antibody drug conjugate that targets the cd30 protein present on lymphoma cells and delivers a toxin designed to promote cancer. Monoclonal antibodies mabs are copies of a single antibody. The nccn compendium is a derivative work of the nccn guidelines. Hepatitis b reactivation with fulminant hepatitis, sometimes fatal screen high risk patients and monitor hbv carriers during and several months after therapy. In one study, 75% of 102 patients treated with brentuximab vedotin saw a response to treatment such as tumor shrinkage. Brentuximab vedotin and lenalidomide for relapsed or. Classical hodgkin lymphoma chl is now considered as one of the hematologic. Progressive multifocal leukoencephalopathy pml see full prescribing information for complete boxed warning. Determine the number of 50 mg vials needed based on the patients weight and the prescribed dose see dosage and administration 2. The adc comprises an anticd30 monoclonal antibody attached by a proteasecleavable linker to a microtubule disrupting agent, monomethyl auristatin e mmae, utilizing. Dec 25, 2017 in germany, they are also studying how to integrate brentuximab vedotin into that regimen to reduce toxicity.
Adcetris brentuximab vedotin is an antibody conjugated drug a combination of three components indicated for treatment of patients with hodgkin lymphoma hodgkins disease and for the treatment of patients with systemic anaplastic large cell lymphoma salcl. It is made up of a monoclonal antibody, a type of protein designed to target and interfere with the growth of cancer cells, and a second drug. Adcetris treatment should start following recovery from asct based on. Easy to read fda package insert, drug facts, dosage and administration, and adverse effects for rituxan rituximab. Promising activity has also been seen in other lymphomas that express cd30. Brentuximab vedotin is given to shrink lymph nodes, alleviate symptoms of hodgkin lymphoma, and achieve disease remission. This allows the chemotherapy to enter and kill the cancer cell. In a pivotal phase ii study, bv was tested as single agent therapy in. Fda has now approved at least four adcs, and hundreds more are in development. Brentuximab vedotin blood american society of hematology. Sequential combination of gemcitabine, vinorelbine, pegylated liposomal doxorubicin and brentuximab as a bridge regimen to transplant in relapsed or refractory hodgkin lymphoma annesophie michallet, 1, yann guillermin, 1, benedicte deau, 2 laure lebras, 1 stephanie harel, 3 sandy amorin, 3 claire reynes, 4 gilles salles, 1, 5. Near complete response in a patient with classical hodgkin. Abstract background brentuximab vedotin is an anticd30 antibodydrug conjugate that has been approved for relapsed and refractory hodgkins lymphoma.
Brentuximab vedotin for treating cd30 positive hodgkins lymphoma. Prior treatment with brentuximab vedotin is allowed provided the patient did not progress on bv or within 30 days of last dose of bv. Brentuximab vedotin inn, trade name adcetris is an antibodydrug conjugate medication used to treat relapsed or refractory hodgkin lymphoma hl and systemic anaplastic large cell lymphoma alcl. Brentuximab vedotin bv is an antibodydrug conjugate adc, comprising an. Jan 25, 2012 brentuximab vedotin adcetris, seattle genetics is a chimeric cd30 antibody conjugated to approximately four molecules of monomethyl auristatin e mmae with a cleavable dipeptide linker. Adcetris is an antibodydrug conjugate composed of a cd30directed monoclonal. Is brentuximab vedotin effective in hodgkin lymphoma. Brentuximab vedotin bc cancer agency cancer drug manual. Role of brentuximab vedotin in the treatment of relapsed or refractory hodgkin lymphoma. When brentuximab vedotin is given to treat hodgkins lymphoma, salcl, or ptcl, it is usually injected once every 3 weeks for as long as your doctor recommends that.
Phase ii trial of brentuximab vedotin as firstline. Patients on the trial were randomly assigned to receive 16 cycles of maintenance bv or placebo every 3 weeks, and one of the most striking outcomes was that the risk of relapse at 2 years was reduced from 55% to 35%. Part 1 of the study is a phase 2, randomized, openlabel, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard rchop chemotherapy rituximab, cyclophosphamide, doxorubicin. Brentuximab vedotin demonstrates objective responses in a phase 2. Seattle genetics pivotal phase ii clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma or alcl shows that at a median follow up of 46. Superior outcomes with brentuximab in cutaneous t cell.
Nonhodgkin lymphomas nhls are a heterogeneous group of hematologic malignancies which typically respond to standard firstline chemoimmunotherapy regimens. Brentuximab vedotin injection comes as a powder to be mixed with fluid and injected over 30 minutes intravenously into a vein by a doctor or nurse in a medical office or hospital. Brentuximab vedotin, an antibody drug conjugate that delivers. Package label of brentuximab vedotin is ndc 5114405001. Concomitant use of brentuximab with bleomycin because of pulmonary toxicity.
For at least 48 hours after you receive a dose, avoid allowing your body fluids to come into contact with your hands or other surfaces. This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. Brentuximab vedotin bv is a key therapeutic agent for patients with. Cd30, a cell membrane protein antibody drug conjugate brentuximab vedotin bv first demonstrated high efficacy in individuals with relapsed hl after asct or in those who were not deemed candidates for intensive therapy. Call your doctor right away if you have a fast or abnormal heartbeat. Monoclonal antibodies seek out cancer cells by targeting particular proteins on. Adcetris brentuximab vedotin for injection package insert. Sequential combination of gemcitabine, vinorelbine, pegylated. Appraisal consultation document brentuximab vedotin for treating cd30positive hodgkins lymphoma issue date.
Study of brentuximab vedotin combined with rchop or rchp in. Dailymed adcetris brentuximab vedotin injection, powder. Brentuximab vedotin is a recombinant chimeric mab directed against cd30 and conjugated through a proteasesensitive linker to monomethyl auristatin e vedotin, which is a microtubule toxin. Please see full prescribing information, including boxed warning.
Retreatment with brentuximab vedotin monotherapy was investigated in patients with cd30positive hodgkin lymphoma hl or systemic anaplastic large cell lymphoma alcl who relapsed after achieving complete or partial remission cr or pr with initial brentuximab vedotin therapy in a previous study clinicaltrials. What should i avoid while receiving brentuximab vedotin adcetris. Patients with classical hodgkin lymphoma experiencing disease. Novel brentuximab vedotin combination therapies show. It is expressed on the surface of hodgkinreedsternberg cells in various. Jc virus infection resulting in pml and death can occur in patients receiving adcetris 5. Side effects of adcetris brentuximab vedotin, warnings, uses. Part 1 of the study is a phase 2, randomized, openlabel, multicenter study designed to evaluate the antitumor activity and safety of brentuximab vedotin when administered in combination with standard rchop chemotherapy rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone.
Unfortunately, patients with refractory nhl face a poor prognosis and represent an unmet need for improved therapeutics. This retrospective study sought to determine if a sequential combination of gvd and brentuximab would be an effective and safe regimen for relapsed or. Adcetris brentuximab vedotin cost, side effects, package. Dec 07, 2014 brentuximab vedotin is an antibodydrug conjugate or adc directed to cd30, which is expressed in classical hodgkin lymphoma hl and systemic alcl, a type of tcell lymphoma. Mar 19, 2014 brentuximab vedotin is a cd30directed antibodydrug conjugate. It selectively targets tumor cells expressing the cd30 antigen, a defining marker of hodgkin lymphoma and alcl a type of t cell nonhodgkin. Brentuximab vedotin is a cd30directed antibodydrug conjugate. Frontline brentuximab plus avd vs standard abvd in advanced. Brentuximab vedotin is an antibodydrug conjugate adc that selectively delivers monomethyl auristatin e mmae into cd30expressing cells.
Get emergency medical help if you have signs of an allergic reaction hives, difficult breathing, swelling in your face or throat or a severe skin reaction fever, sore throat, burning in your eyes, skin pain, red or purple skin rash that spreads and causes blistering and peeling some side effects may occur during the injection or within 24 hours afterward. Brentuximab vedotin for treating cd30 positive hodgkins. Nov 20, 2014 on the basis of the efficacy of brentuximab vedotin as a single agent in hodgkin lymphoma, a study was done using brentuximab vedotin in combination with abvd or avd abvd without bleomycin for up to 6 cycles. Aetna precertification notification 503 sunport lane, orlando, fl 32809. Peripheral neuropathy predominately sensory neuropathy and motor neuropathy reported. Cyp3amediated drugdrug interaction potential and excretion. Sequential combination of gemcitabine, vinorelbine. Brentuximab vedotin bv, or sgn35, is a chimeric anticd30 mab attached by a proteasecleavable linker to a microtubule disrupting agent, monomethyl auristatin e mmae 4, 5. Retreatment with brentuximab vedotin in patients with cd30. Adcetris brentuximab vedotin cost, side effects, package insert. The printed package leaflet of the medicinal product must state the name and. Administer adcetris as an intravenous infusion over 30 minutes every 3 weeks until disease.
Adcetris brentuximab vedotin injectable medication. Rapid desensitization for brentuximab vedotin adceteris allergy. Adcetris is to be used in patients who have received two prior chemotherapy treatments and. Adcetris brentuximab vedotin side effects, images, uses. Infections withhold rituxan and institute appropriate antiinfective therapy 5. For patients with rr chl, novel agents such as bv offer an alternative. Brentuximab adcetrishodgkins lymphoma chemoexperts. Pdf role of brentuximab vedotin in the treatment of. Generic name brentuximab vedotin pronunciation brentuksihmab vehdohtin brand names, other common names adcetristm drug type antibody conjugate how the drug is given intravenously iv brentuximab vedotin is fda approved for the treatment of patients with hodgkin lymphoma after failure of autologous stem cell transplant asct or after failure of at least two prior multiagent. How to use brentuximab vedotin solution, reconstituted recon soln this medication is given by injection into a vein over 30 minutes by a health care professional.
This medicine can pass into body fluids urine, feces, vomit. Cd30 is expressed in a variety of malignancies,14 and is present in 14% to 25%. Brentuximab vedotin adcetris is a cd30directed antibodydrug conjugate adc. Oct 25, 2019 adcetris is available in singleuse vials when reconstituted with 10. The words information redacted, where they appear in this document, indicate that confidential information has been deleted. Successful rapid desensitization to the antibodydrug conjugate brentuximab vedotin in a patient with refractory hodgkin lymphoma. Tell your doctor if you have ever had an unusual or. Based on this background, a sequential combination of gvd and brentuximab have been used in some french centres as a bridge to transplant after either a bleomycin or platinum based regimen. This study evaluated the cyp3amediated drugdrug interaction potential of brentuximab vedotin and the excretion of mmae. January 20 to add approximately 15 patients with histologically confirmed dlbcl. Following reconstitution, dilute immediately into an infusion bag.
The authors and the publisher have exerted every effort to. The publisher is not responsible for the content or. Rituxan rituximab is indicated, in combination with fludarabine and cyclophosphamide fc, for the treatment of patients with previously untreated and previously treated cd20positive cll. Easy to read fda package insert, drug facts, dosage and administration, and adverse effects for rituxan rituximab skip to.
Here in north america, we want to integrate it into the abvd recipe. Results of the phase 3 aethera trial of brentuximab. It selectively targets tumor cells expressing the cd30 antigen, a defining marker of hodgkin lymphoma and alcl a type of t cell nonhodgkin lymphoma. Adcetris, innbrentuximab vedotin european medicines agency. Brentuximab vedotin for the treatment of patients with relapsed or. Brentuximab adcetris general cancer information cancer.
663 1261 887 232 664 33 755 1429 364 661 898 1514 154 1467 1658 1284 818 134 22 179 438 1530 347 147 168 874 454 1011 537 138 1134 1046 449 194 762 863 1025 948 1295 242 1373 1044 1430